Publisher
Springer International Publishing
Reference107 articles.
1. Eichler HG, Bloechl-Daum B, Brasseur D, Breckendridge H, Leufkers H, Raine J, et al. The risks of risk aversion in drug regulation. Nature Revs Drug Discover. 2013;12:907-15.
2. Bauer P, Köning F. The risks of methodology aversion in drug regulation. Nature Revs Drug Discover. 2014;13:317-8.
3. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative benefit-risk methodology project for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health. 2010;13:657-66.
4. European Medicines Agency (EMA). Benefit-risk methodology project. Work package 5 report: field tests. 2001. Available at:
http://www.ema.europa.eu/docs/enGB/documentlibrary/Report/2011/09/WC500112088.pdf
.
5. Mestre-Ferrándiz J, Deverka P, Pistollato M, Rosenberg E. The current drug development paradigm: Responding to US and European demands for evidence of comparative effectiveness and relative effectiveness. London: Office of Health Economics; 2014.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献